Skip to main content
. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563

Fig. 2.

Fig. 2

Time courses for absolute change from baseline in levels of plasminogen activator inhibitor-1, platelets, and high-sensitivity C-reactive protein.

Significance is indicated by asterisks: ∗p <0.05, ∗∗p <0.01 vs. placebo (MMRM). The vertical line at week 16 indicates the end of the treatment period, with safety follow-up continuing to week 20.